SG11202108619SA - Tyk2 pseudokinase ligands - Google Patents
Tyk2 pseudokinase ligandsInfo
- Publication number
- SG11202108619SA SG11202108619SA SG11202108619SA SG11202108619SA SG11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA SG 11202108619S A SG11202108619S A SG 11202108619SA
- Authority
- SG
- Singapore
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- pseudokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802642P | 2019-02-07 | 2019-02-07 | |
| PCT/US2020/017314 WO2020163778A1 (en) | 2019-02-07 | 2020-02-07 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108619SA true SG11202108619SA (en) | 2021-09-29 |
Family
ID=71947508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108619SA SG11202108619SA (en) | 2019-02-07 | 2020-02-07 | Tyk2 pseudokinase ligands |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220135567A1 (en) |
| EP (1) | EP3920931A4 (en) |
| JP (1) | JP2022519696A (en) |
| KR (1) | KR20210124409A (en) |
| CN (1) | CN113677347A (en) |
| AU (1) | AU2020218267A1 (en) |
| CA (1) | CA3129438A1 (en) |
| IL (1) | IL285429A (en) |
| MX (1) | MX2021009555A (en) |
| SG (1) | SG11202108619SA (en) |
| WO (1) | WO2020163778A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022505987A (en) | 2018-10-22 | 2022-01-14 | エスカー セラピューティクス，インコーポレイテッド | TYK2 inhibitors and their use |
| JP2022529311A (en) | 2019-03-26 | 2022-06-21 | ベンティックス バイオサイエンシーズ，インク． | TYK2 pseudokinase ligand |
| EP4054581A4 (en) | 2019-11-08 | 2023-11-22 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| CN117043164A (en) * | 2021-01-19 | 2023-11-10 | 安锐生物医药科技(广州)有限公司 | Imidazopyridazine or pyrazolopyrimidine compounds and compositions |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050115252A (en) * | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | Pyrazolo[1,5-a]pyrimidine derivatives |
| TW201720828A (en) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | Therapeutic compounds and compositions, and methods of use thereof |
| EP4338802A2 (en) * | 2017-03-08 | 2024-03-20 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| TW201900648A (en) * | 2017-05-22 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | Therapeutic compounds and compositions and methods of use thereof |
| CN111194317A (en) * | 2017-07-28 | 2020-05-22 | 林伯士拉克许米公司 | TYK2 inhibitor and application thereof |
| WO2020055636A1 (en) * | 2018-09-10 | 2020-03-19 | Eli Lilly And Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| CA3115088A1 (en) * | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI800696B (en) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives |
-
2020
- 2020-02-07 KR KR1020217028660A patent/KR20210124409A/en unknown
- 2020-02-07 WO PCT/US2020/017314 patent/WO2020163778A1/en unknown
- 2020-02-07 AU AU2020218267A patent/AU2020218267A1/en active Pending
- 2020-02-07 SG SG11202108619SA patent/SG11202108619SA/en unknown
- 2020-02-07 EP EP20752194.9A patent/EP3920931A4/en active Pending
- 2020-02-07 US US17/428,953 patent/US20220135567A1/en active Pending
- 2020-02-07 MX MX2021009555A patent/MX2021009555A/en unknown
- 2020-02-07 JP JP2021546005A patent/JP2022519696A/en active Pending
- 2020-02-07 CA CA3129438A patent/CA3129438A1/en active Pending
- 2020-02-07 CN CN202080026979.3A patent/CN113677347A/en active Pending
-
2021
- 2021-08-08 IL IL285429A patent/IL285429A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220135567A1 (en) | 2022-05-05 |
| AU2020218267A1 (en) | 2021-09-30 |
| JP2022519696A (en) | 2022-03-24 |
| MX2021009555A (en) | 2021-10-13 |
| EP3920931A1 (en) | 2021-12-15 |
| CA3129438A1 (en) | 2020-08-13 |
| CN113677347A (en) | 2021-11-19 |
| EP3920931A4 (en) | 2022-08-10 |
| KR20210124409A (en) | 2021-10-14 |
| IL285429A (en) | 2021-09-30 |
| WO2020163778A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286635A (en) | Tyk2 pseudokinase ligands | |
| IL285429A (en) | Tyk2 pseudokinase ligands | |
| ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
| GB202018087D0 (en) | No details | |
| GB202013426D0 (en) | No Details | |
| EP4054581A4 (en) | Tyk2 pseudokinase ligands | |
| GB202017837D0 (en) | No details | |
| IL285791A (en) | Intent-driven contact center | |
| IL288378A (en) | 18f-radiolabeled biomolecules | |
| GB202015405D0 (en) | No details | |
| IL288304A (en) | Disc pump | |
| GB201900566D0 (en) | Carrier | |
| EP3766640C0 (en) | Magnetic base | |
| GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
| EP4055020A4 (en) | Radiolabelled targeting ligands | |
| PL3845343T3 (en) | Magnetic base | |
| GB202006205D0 (en) | No details | |
| GB201903058D0 (en) | Adsorption | |
| GB202014354D0 (en) | No details | |
| GB2587869B (en) | Carrier | |
| GB201913937D0 (en) | Ligand Design | |
| GB201904518D0 (en) | Uvvyowgbrir circular | |
| GB201918871D0 (en) | Complexes | |
| GB201810321D0 (en) | Peptide ligands for bindingto EphA2 | |
| GB201911303D0 (en) | Moleculaer complexes |